title: [Anemia in lymphoma].
abstract: Anaemia is frequently associated with lymphoma. Many causes are implicated and can sometimes be associated to each other so that the level of haemoglobin is often very low. In follicular lymphoma, the level of haemoglobin remains an independent predictive prognostic factor. Likewise, anaemia seems correlated to survival for both Hodgkin's and non-Hodgkin's lymphomas. However, therapeutic strategies to control anaemia remain somewhat unsatisfactory. Thus, recombinant erythropoietin might be an effective drug to increase the haemoglobin rate, limit the transfusional risk and improve patients' quality of life.
authors.affiliation: Département de Gynécologie, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94 800 Villejuif. tybdlmr@yahoo.fr
authors.forename: Thibault
authors.initials: T
authors.lastname: de La Motte Rouge
authors.forename: Maurice
authors.initials: M
authors.lastname: Schneider
mesh_terms: D000740:Anemia / Q000097:blood / Q000209:etiology*; D001803:Blood Transfusion; D004921:Erythropoietin / Q000627:therapeutic use; D005221:Fatigue / Q000209:etiology; D006441:Hemoglobin A / Q000378:metabolism; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000628:therapy; D011379:Prognosis; D011788:Quality of Life; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D006441:Hemoglobin A